News Sentiment

LNAI sentiment intelligence

Lunai Bioworks Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.78 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+56.8% over one week, +67.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

$Lunai Bioworks (LNAI.US)$

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 56.8% Price confirming higher
Trend fit Trend inactive 67.3% over four weeks
Fair value -95.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 25
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
TradingView 6
Market source 5
Moomoo 3
PR Newswire 3
Investing.com 2
simplywall.st 2
Blockonomi 1

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 9
Regulatory and legal 5
Deals and strategy 2
Guidance 1
Analyst action 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
Moomoo Direct company coverage

$Lunai Bioworks (LNAI.US)$

An investor expresses confidence in Lunai Bioworks (LNAI.US), stating that buyers will return and the stock will build momentum for a future run-up. The comment suggests an optimistic outlook for the company's stock performance. This short post is part of the moomoo Community fee

Tone
Positive 77/100
Event
Guidance
Published
17 Jun 2026 22:39
Source
Moomoo
Stock Titan Direct company coverage

Lunai Bioworks touts defense revenue, neurology pipeline, lawsuit

Lunai Bioworks' CEO has provided an update on the company's progress, highlighting its first revenue-generating U.S. defense contract through BioSymetrics, advancements in its Augusta AI neurology platform for epilepsy, Parkinson's, and Alzheimer's, and ongoing litigation against

Tone
Positive 66/100
Event
Regulatory and legal
Published
17 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

[8-K] Lunai Bioworks Inc. Reports Material Event

Lunai Bioworks Inc. (LNAI) filed an 8-K report detailing a material event, specifically the issuance of a letter to shareholders on June 17, 2026. This letter outlines the company's strategic advancements in biodefense and precision neurology, highlighted by a revenue-generating

Tone
Positive 67/100
Event
Market update
Published
17 Jun 2026 20:32
Source
Stock Titan
TradingView Direct company coverage

Lunai Bioworks secures first revenue defense contract, files expedited discovery in naked shorting suit

Lunai Bioworks (LNAI) announced its first revenue-generating, multi-year U.S. defense collaboration with BioSymetrics for AI-enabled chemical threat assessment. The company also filed for expedited discovery in a lawsuit alleging naked short selling, citing evidence of 29.6 milli

Tone
Positive 72/100
Event
Regulatory and legal
Published
17 Jun 2026 20:10
Source
TradingView
Blockonomi Direct company coverage

Lunai Bioworks (LNAI) Stock Soars 81% on Nasdaq Compliance Restoration

Lunai Bioworks (LNAI) shares surged over 80% in after-hours trading after Nasdaq officially recognized the company's return to compliance with the $1.00 minimum bid price rule. While this restores their listing, the company now enters a strict one-year monitoring period where fal

Tone
Positive 71/100
Event
Market update
Published
17 Jun 2026 13:42
Source
Blockonomi
www.timothysykes.com Direct company coverage

LNAI Stock Sees Volatile Spike As Traders Zero In On Risk

Lunai Bioworks Inc Com (LNAI) stock experienced a volatile spike, trading up by 74.6% due to favorable biotech innovation news, despite weak financials. The company shows minimal revenue, significant operating losses, and a poor balance sheet, making it a high-risk, high-volatili

Tone
Positive 63/100
Event
Earnings
Published
17 Jun 2026 13:42
Source
www.timothysykes.com
StocksToTrade Direct company coverage

LNAI Stock Explodes On Volume As Traders Target Volatility

Lunai Bioworks Inc (LNAI) stock surged by 61.16% on high volume, driven by positive sentiment and momentum trading despite poor fundamentals. The company reported minimal revenue, significant losses, and negative equity, making it a speculative play for short-term traders targeti

Tone
Positive 62/100
Event
Earnings
Published
17 Jun 2026 13:42
Source
StocksToTrade
TechStock² Direct company coverage

Lunai Bioworks stock jumps after Nasdaq bid-price compliance filing

Lunai Bioworks shares surged after Nasdaq confirmed the company's compliance with the $1 minimum bid-price rule, a crucial step for maintaining its listing. Despite this, Lunai remains under a one-year Nasdaq panel monitor and faces ongoing capital needs, reporting a significant

Tone
Positive 82/100
Event
Market update
Published
17 Jun 2026 12:42
Source
TechStock²
Moomoo Direct company coverage

Trending Stocks Today | Lunai Bioworks Surges 151.66% Pre-Market

Lunai Bioworks saw a significant surge of 151.66% in pre-market trading, driven by the announcement of an exclusive licensing agreement for its lead gene therapy program, LNAI-201, with Takeda Pharmaceutical. This agreement targets rare neurological genetic disorders, providing a

Tone
Positive 95/100
Event
Market update
Published
17 Jun 2026 08:13
Source
Moomoo
TradingKey Direct company coverage

Lunai Bioworks Ord Shs (LNAI) Institutional Confidence

This article provides details on the institutional confidence in Lunai Bioworks Ord Shs (LNAI), presenting a list of major institutional shareholders and their shareholdings, including changes in their positions. Key shareholders like RS Group ApS and Lakysa Ventures, Inc. are hi

Tone
Positive 62/100
Event
Market update
Published
17 Jun 2026 03:40
Source
TradingKey
TradingView Direct company coverage

Lunai regains Nasdaq $1.00 bid-price compliance; one-year Panel monitoring imposed

Lunai Bioworks (LNAI) has successfully regained compliance with Nasdaq's minimum $1.00 bid-price rule. As a result, the company will be subject to a mandatory one-year monitoring period by the Nasdaq Panel. During this monitoring period, if Lunai again violates the bid-price rule

Tone
Positive 62/100
Event
Market update
Published
16 Jun 2026 20:03
Source
TradingView
Stock Titan Direct company coverage

Lunai Bioworks (NASDAQ: LNAI) back in bid compliance but under 1-year Nasdaq monitor

Lunai Bioworks (LNAI) has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as confirmed by Nasdaq. The company will now be under a mandatory one-year monitoring period, during which any future non-compliance with the bid price rule will result i

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 19:59
Source
Stock Titan
Quiver Quantitative Direct company coverage

Lunai Bioworks Inc Stock Short Interest Rises to 62.94%

Lunai Bioworks Inc (LNAI) saw its short interest increase to 62.94% of the float on May 15th, representing a 50.51% rise from April 30th. This means 2,489,634 shares were held short, and it would take an estimated 1.0 days for short sellers to cover their positions. Institutional

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 13:28
Source
Quiver Quantitative
Investing.com UK Direct company coverage

Lunai Bioworks partners with BrainStorm on neurology drug discovery

Lunai Bioworks' subsidiary BioSymetrics has partnered with BrainStorm Therapeutics to identify and validate new treatments for neurological diseases, focusing initially on rare genetic epilepsies and neurodegenerative conditions like Parkinson's disease. The collaboration leverag

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 15:38
Source
Investing.com UK
Stock Titan Direct company coverage

AI and human brain organoids join forces on Parkinson's, rare epilepsy

Lunai Bioworks, through its subsidiary BioSymetrics, and BrainStorm Therapeutics have launched a collaboration to discover and validate therapeutic targets for neurological diseases like Parkinson's and rare genetic epilepsies. This partnership leverages AI target discovery, huma

Tone
Positive 72/100
Event
Analyst action
Published
28 May 2026 14:10
Source
Stock Titan
PR Newswire Direct company coverage

Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

Lunai Bioworks and BrainStorm Therapeutics are collaborating to discover and develop novel therapies for neurological diseases, including Parkinson's and rare genetic epilepsies. The partnership, supported by a grant from the LouLou Foundation, combines BioSymetrics' AI-driven ta

Tone
Positive 71/100
Event
Deals and strategy
Published
28 May 2026 13:10
Source
PR Newswire
TradingView Direct company coverage

Pretax income of Lunai Bioworks, Inc. – LS:A42CL6

This article displays the pretax income for Lunai Bioworks, Inc. (A42CL6), a biotechnology company listed on the Lang & Schwarz Tradecenter. The specific financial values are not provided within the snippet, but the article indicates it is a financial data point for the company.

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 11:10
Source
TradingView
TradingView Direct company coverage

Lunai Bioworks, Inc. Cash Flow – LS:A42CL6

This article provides key cash flow information for Lunai Bioworks, Inc. (A42CL6), indicating a free cash flow of -888.77K EUR for Q3 2026 and -6.68M EUR for the full year 2025, with operating cash flow also at -6.68M EUR for 2025. It presents a historical overview of cash from o

Tone
Negative 17/100
Event
Balance sheet
Published
28 May 2026 11:10
Source
TradingView
Moomoo Direct company coverage

Lunai Bioworks Company Profile & Introduction

This document is a placeholder for the company profile and introduction of Lunai Bioworks. It indicates that further details about the company will be provided within this section.

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 23:40
Source
Moomoo
TradingView Direct company coverage

Lunai Bioworks, Inc. Financial Disclosures & SEC Filings

This article provides a comprehensive list of Lunai Bioworks Inc.'s SEC filings and other financial documents. It includes various forms such as 10-K (Annual Report) and 10-Q (Quarterly Report), investor presentations, and event transcripts dating back to 2014. The information is

Tone
Neutral 50/100
Event
Market update
Published
24 May 2026 19:40
Source
TradingView
PR Newswire Direct company coverage

Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock

A federal judge in Delaware has granted Lunai Bioworks, Inc.'s motion for expedited discovery to identify "John Doe" defendants involved in alleged "naked" short-selling of the company's common stock. This action seeks to hold those responsible accountable for securities fraud an

Tone
Positive 80/100
Event
Regulatory and legal
Published
22 May 2026 13:39
Source
PR Newswire
The Globe and Mail Direct company coverage

Lunai Bioworks Announces 1-for-8 Reverse Stock Split

Lunai Bioworks (LNAI) announced a 1-for-8 reverse stock split of its common shares, effective May 22, 2026, to restore compliance with Nasdaq's minimum bid requirement. This action will reduce outstanding shares from approximately 36.3 million to 4.5 million, with proportional ad

Tone
Negative 28/100
Event
Market update
Published
21 May 2026 13:41
Source
The Globe and Mail
Investing.com Direct company coverage

Lunai Bioworks stock falls after reverse split announcement

Lunai Bioworks Inc. (NASDAQ:LNAI) shares dropped 12.6% after announcing a 1-for-8 reverse stock split set to take effect on May 22, 2026. This move aims to increase the stock price to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse sp

Tone
Negative 29/100
Event
Market update
Published
21 May 2026 09:41
Source
Investing.com
MSN Direct company coverage

Lunai Bioworks to implement 1-for-8 reverse stock split

Lunai Bioworks announced a 1-for-8 reverse stock split of its common stock, effective May 21, 2026. The company's ticker symbol "LUNA" will remain unchanged, but the CUSIP number will change to 55042D209. The reverse stock split aims to increase the per-share trading price to mee

Tone
Neutral 50/100
Event
Market update
Published
20 May 2026 15:40
Source
MSN
Investing.com Nigeria Direct company coverage

Lunai Bioworks stock falls after reverse split announcement By Investing.com

Lunai Bioworks Inc. (NASDAQ:LNAI) shares dropped 12.6% after announcing a 1-for-8 reverse stock split set to take effect on May 22, 2026. This action is intended to increase the stock price to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The r

Tone
Negative 13/100
Event
Market update
Published
20 May 2026 14:34
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Lunai Bioworks (NASDAQ: LNAI) plans 1-for-8 reverse split to meet Nasdaq price rule

Lunai Bioworks (NASDAQ: LNAI) announced a 1-for-8 reverse stock split, effective May 22, 2026, to regain compliance with Nasdaq's minimum bid price rule of $1.00 per share. This action will reduce outstanding shares from approximately 36.3 million to 4.5 million, with fractional

Tone
Negative 40/100
Event
Market update
Published
20 May 2026 13:40
Source
Stock Titan